GENE up on Rauch coverage

Genome Therapeutics (GENE) was up $4 (42%) to $13.50 on Wednesday after Ladenburg Thalmann analyst Albert Rauch began coverage of the genomics company with a "strong buy" and an $84 price target. He said that the company, which uses pathogen genomes to discover anti-infective drugs, has attracted $294 million in potential collaborative funding from six partnerships. ...